{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=14",
    "query": {
      "condition": "Breast Cancer",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 7077,
    "total_pages": 708,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T23:48:01.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03202472",
      "title": "Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Neoplasm",
        "Lesion"
      ],
      "interventions": [
        {
          "name": "Implanted Medical Device",
          "type": "DEVICE"
        },
        {
          "name": "Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiofrequency (RFID) -Guided Localization",
          "type": "PROCEDURE"
        },
        {
          "name": "Ultrasonography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2017-08-03",
      "completion_date": "2019-02-01",
      "has_results": true,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03202472"
    },
    {
      "nct_id": "NCT00003877",
      "title": "Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "in vitro-treated bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 64 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "1998-09",
      "completion_date": "2000-12",
      "has_results": false,
      "last_update_posted_date": "2011-03-07",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • Buffalo, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003877"
    },
    {
      "nct_id": "NCT01514565",
      "title": "Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2011-12",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-18",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01514565"
    },
    {
      "nct_id": "NCT04594473",
      "title": "A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Comprehensive Oncology Rehabilitation and Exercise (CORE) Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2021-03-24",
      "completion_date": "2023-11-10",
      "has_results": false,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04594473"
    },
    {
      "nct_id": "NCT02154529",
      "title": "Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HER-2 Positive Breast Cancer",
        "Metastatic Malignant Neoplasm to Brain"
      ],
      "interventions": [
        {
          "name": "Tesevatinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kadmon Corporation, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2014-05",
      "completion_date": "2015-09-13",
      "has_results": true,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Indianapolis, Indiana • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Farmington",
          "state": "New Mexico"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02154529"
    },
    {
      "nct_id": "NCT07038369",
      "title": "A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Breast Cancer",
        "Breast Carcinoma",
        "Breast Neoplasms",
        "ER Positive Breast Cancer",
        "Cervical Cancers",
        "Cervical Neoplasms",
        "Cervical Carcinoma",
        "Triple Negative Breast Cancer",
        "Gynecologic Cancers",
        "Gynecologic Neoplasm",
        "Endometrial Cancer",
        "Endometrial Neoplasm",
        "Endometrial Carcinoma (EC)",
        "Fallopian Cancer",
        "Ovarian Carcinoma",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Prostate Cancers",
        "Prostate Carcinoma",
        "Solid Tumors",
        "Neoplasms",
        "Neoplasms by Site",
        "Breast Diseases",
        "Uterine Neoplasms",
        "Genital Neoplasms, Female",
        "Urogenital Neoplasms"
      ],
      "interventions": [
        {
          "name": "ATV-1601",
          "type": "DRUG"
        },
        {
          "name": "ATV-1601 + Fulvestrant",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Atavistik Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2025-07-29",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Lake Mary, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07038369"
    },
    {
      "nct_id": "NCT05169437",
      "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Breast Tumor",
        "Colon Tumor, Malignant",
        "Lung Tumor",
        "Urologic Cancer",
        "Pancreatic Cancer",
        "Melanoma",
        "Metastatic Cancer",
        "Locally Advanced Solid Tumor",
        "Esophageal Cancer",
        "Endometrial Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tempus AI",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2022-03-15",
      "completion_date": "2024-08-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 80,
      "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more",
      "locations": [
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05169437"
    },
    {
      "nct_id": "NCT07332975",
      "title": "ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2026-01-20",
      "completion_date": "2029-01-20",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07332975"
    },
    {
      "nct_id": "NCT03344965",
      "title": "Olaparib In Metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Invasive Breast Cancer",
        "Somatic Mutation Breast Cancer (BRCA1)",
        "Somatic Mutation Breast Cancer (BRCA2)",
        "CHEK2 Gene Mutation",
        "ATM Gene Mutation",
        "PALB2 Gene Mutation",
        "RAD51 Gene Mutation",
        "BRIP1 Gene Mutation",
        "NBN Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2018-04-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03344965"
    },
    {
      "nct_id": "NCT01129336",
      "title": "Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "First or Second Line HER2-negative Breast Cancer",
        "Metastatic Disease Without Bone Metastasis"
      ],
      "interventions": [
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 44,
      "start_date": "2010-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-20",
      "last_synced_at": "2026-10-28T23:48:01.855Z",
      "location_count": 33,
      "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 30 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Verne",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01129336"
    }
  ]
}